ABBVAbbVieRunning, no new patients
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 89 (final count)
- Started
- Jan 11, 2024
- Main results expected
- Jan 2027
- Fully finished
- Jan 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Stage 1: Best Overall Response (BOR) per Investigator
Measured over: Through Study Completion, Up to Approximately 56 Months
Stage 2: Overall Survival (OS)
Measured over: Through Study Completion, Up to Approximately 56 Months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06109272 · record last updated 2026-09-22 · checked 2026-11-09 15:47 UTC